RYTM | tickerfilter.com

Fundamental analysis

21%

Profitability 25%

Dept financing 2%

Liquidity 50%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-1.50%

1 Month

-10.05%

3 Months

-11.09%

6 Months

-6.26%

1 Year

84.13%

2 Year

124.43%

Key data

Stock price

$93.52

P/E Ratio

0.00

DAY RANGE

$89.52 - $94.26

EPS

-$3.11

52 WEEK RANGE

$45.90 - $122.20

52 WEEK CHANGE

$92.59

MARKET CAP

7.143 B

YIELD

N/A

SHARES OUTSTANDING

68.285 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

08-05-2025

BETA

1.78

PUBLIC FLOAT

AVERAGE 10 VOLUME

$957,887

AVERAGE 30 VOLUME

$812,996

Company detail

CEO: David P. Meeker
Region: US
Website: rhythmtx.com
Employees: 140
IPO year: 2017

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Rhythm Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency.

RYTM - RHYTHM PHARMACEUTICALS, INC.